HCV Policy & Advocacy
AASLD 2017: TAF for Hepatitis B Improves Kidney Function and Bone Loss
- Details
- Category: HBV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by Liz Highleyman
Tenofovir alafenamide (TAF) remains effective against hepatitis B virus (HBV) for 96 weeks, with no resistance detected, according to studies presented at the 2017 AASLD Liver Meeting last month in Washington, DC.
AASLD 2017: More Work and Lower Drug Prices Needed to Eliminate Hepatitis C Worldwide
- Details
- Category: HCV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by Liz Highleyman
Eliminating hepatitis C virus (HCV) as a global public health concern is feasible, but to do so more people need to be tested and treated, and prices of direct-acting antivirals need to come down, according to presentations at the AASLD Liver Meeting last month in Washington, DC.
AASLD 2017: REP 2139 Combination Therapy Leads to Functional Control of Hepatitis B Virus
- Details
- Category: HBV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by Liz Highleyman
A majority of chronic hepatitis B patients treated with a nucleic acid polymer (REP 2139 or REP 2165) plus tenofovir and pegylated interferon were able to achieve "functional control" of hepatitis B virus (HBV), according to a late-breaking poster presentation at the 2017 AASLD Liver Meeting last month in Washington, DC.
AASLD 2017: TAF for Hepatitis B Improves Kidney Function and Bone Loss
- Details
- Category: HBV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by Liz Highleyman
Tenofovir alafenamide (TAF) remains effective against hepatitis B virus (HBV) for 96 weeks, with no resistance detected, according to studies presented at the 2017 AASLD Liver Meeting last month in Washington, DC.
U.S. Approves New Hepatitis B Vaccine as Public Health Agencies Update Guidelines
- Details
- Category: HBV Vaccines
- Published on Thursday, 30 November 2017 00:00
- Written by Liz Highleyman
On November 9 the U.S. Food and Drug Administration(FDA) approved Heplisav-B, a new vaccine that provides protection against all known subtypes of hepatitis B virus (HBV) with 2 rather than 3 doses, which is expected to reduce the number of people who do not complete the vaccine series.
More Articles...
- EASL 2017: European HCV Treatment Access Survey Shows Big Variations in Eligibility
- HIV Glasgow: Tests of Online PrEP Purchases Find No Fakes and Adequate Drug Levels
- HIV Glasgow: Generic Hepatitis C Drugs Purchased Online Produce High Cure Rates
- HIV Glasgow: French Study Reveals Growing Complexity of Medical Needs as People with HIV Age
Web Design and Development by